S
RETA

SignatureFD’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

SignatureFD’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-99
Closed -$10.1K – 3347
2023
Q2 		$10.1K Buy
99
+6
+6% +$568 ﹤0.01% 2233
2023
Q1 		$8.46K Buy
93
+8
+9% +$469 ﹤0.01% 2286
2022
Q4 		$3.23K Buy
85
+25
+42% +$860 ﹤0.01% 2641
2022
Q3 		$2K Sell
60
-58
-49% -$1.61K ﹤0.01% 2881
2022
Q2 		$4K Sell
118
-157
-57% -$4.68K ﹤0.01% 2569
2022
Q1 		$9K Buy
+275
New +$8.16K ﹤0.01% 2234
2021
Q4 		– Sell
-35
Closed -$4K – 3324
2021
Q3 		$4K Sell
35
-8
-19% -$938 ﹤0.01% 2477
2021
Q2 		$6K Buy
43
+18
+72% +$2.03K ﹤0.01% 2244
2021
Q1 		$2K Buy
25
+16
+178% +$1.87K ﹤0.01% 2559
2020
Q4 		$1K Sell
9
-5
-36% -$657 ﹤0.01% 2508
2020
Q3 		$1K Buy
+14
New +$1.75K ﹤0.01% 2535

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SignatureFD's RETA Position: Q3 2023 in Review

SignatureFD sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 99 shares — an estimated $10.1K sold.

SignatureFD first reported a position in RETA in Q3 2020 and held it in 11 quarters. The position peaked at $10.1K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • SignatureFD reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • SignatureFD sold 99 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $10.1K.
  • SignatureFD first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020 and held it in 11 quarters.
  • SignatureFD's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10.1K in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on SignatureFD's 13F filing for Q3 2023, filed 3 Nov 2023.